Skip to content

Evaluation of an Oral Nutritional Supplement

Evaluation of an Oral Nutritional Supplement With a New Protein Blend

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01781624
Enrollment
25
Registered
2013-02-01
Start date
2012-10-31
Completion date
2012-11-30
Last updated
2013-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro-intestinal Tolerance

Brief summary

The objective of this study is to evaluate gastrointestinal tolerance of an oral nutritional supplement containing a new protein blend in healthy elderly subjects.

Interventions

Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

Subjects will be eligible for the study if they meet all of the following inclusion criteria: 1. Age ≥ 60 and ≤ 90 years 2. Body Mass Index (BMI) \> 20 but \< 35

Exclusion criteria

Subjects will be excluded from the study if they meet any of the following criteria: 1. History of diabetes 2. Currently taking or has taken antibiotic within 1 week prior to enrollment 3. Major surgery less than 3 months prior to enrollment in the study 4. Current active malignant disease or was treated within the last 6 months for cancer 5. Immunodeficiency disorder 6. Myocardial infarction within the last 3 months prior to enrollment 7. Chronic obstructive pulmonary disease (COPD) 8. Allergy to any of the ingredients in the study product 9. Aversion to flavor of product being tested 10. Obstruction of the gastrointestinal tract precluding ingestion or absorption of the study product, inflammatory bowel disease, ulcer, gastric reflux disease, short bowel syndrome, or other major gastrointestinal disease 11. Dementia, brain metastases, eating disorders, history of significant neurological or psychiatric disorder 12. Pursuing or has unintentional weight loss or weight gain ≥ 5% in last 4 weeks 13. Medications/dietary supplements/substances that could profoundly modulate metabolism or affect GI motility

Design outcomes

Primary

MeasureTime frameDescription
Gastro-Intestinal ToleranceStudy Day 1-7Self-reported questionnaire

Secondary

MeasureTime frameDescription
Study Product ComplianceStudy Day 1-7Self-reported number of containers consumed per day
WeightStudy Day 1 and 8

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026